Relationship of age and dialysis profiles of to serum concentrations of PFOA and PFOS in uremic patients using linear regression (n = 126).

<p>Relationship of age and dialysis profiles of to serum concentrations of PFOA and PFOS in uremic patients using linear regression (n = 126).</p

Linear regression of hemodialysis (HD) duration (hours) (p = 0.029) (A), Karnofsky performance status score for activities of daily living (ADL) (p = 0.008) (B), serum cholesterol (mg/dl) (p = 0.011) (C) and chloride (Cl) (mEq/L) (p = 0.013) (D) (X-axis) with serum PFOS concentration (ng/ml) (Y-axis) (all p <0.05).

<p>Linear regression of hemodialysis (HD) duration (hours) (p = 0.029) (A), Karnofsky performance status score for activities of daily living (ADL) (p = 0.008) (B), serum cholesterol (mg/dl) (p = 0.011) (C) and chloride (Cl) (mEq/L) (p = 0.013) (D) (X-axis) with serum PFOS concentration (ng/ml) (Y-axis) (all p <0.05).</p

Comparisons of patient data and medication profiles with PFOA and PFOS levels in different subgroups of uremic patients using the independent t-test (n = 126).

<p>Comparisons of patient data and medication profiles with PFOA and PFOS levels in different subgroups of uremic patients using the independent t-test (n = 126).</p

Relationship of hemogram and biochemical profiles to serum concentrations of PFOA and PFOS in uremic patients using linear regression.

<p>Relationship of hemogram and biochemical profiles to serum concentrations of PFOA and PFOS in uremic patients using linear regression.</p

Comparison of PFOA and PFOS concentrations in uremic patients (n = 126) before (pre HD) and after HD (post HD) (ng/ml) (p = 0.707 for PFOA, p = 0.001 for PFOS) (* compared with pre-HD value with paired t–test, p<0.05).

<p>Comparison of PFOA and PFOS concentrations in uremic patients (n = 126) before (pre HD) and after HD (post HD) (ng/ml) (p = 0.707 for PFOA, p = 0.001 for PFOS) (* compared with pre-HD value with paired t–test, p<0.05).</p

Linear regression of ferritin (ng/ml) (p<0.001) (A), mean corpuscular volume (MCV) (fl) (p = 0.023) (B), protein (g/dl) (p = 0.005) (C) and Ca (mg/dl) (p = 0.012) (D) (X axis) with serum PFOS concentration (ng/ml) (Y axis) (all p <0.05).

<p>Linear regression of ferritin (ng/ml) (p<0.001) (A), mean corpuscular volume (MCV) (fl) (p = 0.023) (B), protein (g/dl) (p = 0.005) (C) and Ca (mg/dl) (p = 0.012) (D) (X axis) with serum PFOS concentration (ng/ml) (Y axis) (all p <0.05).</p

Product ion scan of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS).

<p>Product ion scan of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS).</p

Demographic data of exacerbation of chronic obstructive pulmonary disease cases from 1999 to 2009 in Taiwan.

*<p>Inhaled medicine included: inhaled long-acting ß₂ agonist, long-acting muscarinic antagonist or/and inhaled corticosteroids.</p

Odds ratios of exacerbation of chronic obstructive pulmonary disease relative to the entire range of mean temperatures.

<p> <b>*</b><b><i>P</i></b><b><0.05.</b></p

Odds ratios of exacerbation of chronic obstructive pulmonary disease in relation to meteorological variables.

*<p>Mean meteorological data of the same day and 2 previous days.</p>**<p>Mean meteorological data of the same day and 6 previous days.</p>+<p>Mean meteorological data of the same day and 13 previous days.</p>++<p>Mean meteorological data of the same day and 27 previous days.</p>#<p>Decrease per 5°C.</p